Skip to main content
SpringerLink
Log in

Defining the high-risk breast cancer patient

  • Chapter
Adjuvant Therapy of Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 60))

Abstract

Predicting the clinical course of a primary breast tumor is very problematic. Some patients are cured by local therapy and survive for many years. Other patients experience a rapid deterioration with early recurrence of their disease, followed shortly by death. It would obviously be useful to be able to identify individual patients who are at high or low risk for relapse in order to plan the appropriate management of the patient’s breast cancer. Patients with a low probability of recurrence could be spared the potential toxicities associated with therapeutic regimens, while patients who are likely to recur could be given the option of aggressive adjuvant therapy. However, before optimal treatment strategies can be initiated, it is also necessary to know which patients are likely to benefit from specific treatment regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adjuvant chemotherapy for breast cancer. JAMA 254:3461–3463, 1985.

    Article  Google Scholar 

  2. Clinical alert from the National Cancer Institute, May 18, 1988. Breast Cancer Res Treat 12:3–5, 1988.

    Google Scholar 

  3. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473–478, 1989.

    Article  PubMed  CAS  Google Scholar 

  4. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484, 1989.

    Article  PubMed  CAS  Google Scholar 

  5. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An Intergroup study. N Engl J Med 320:485–490, 1989.

    Article  PubMed  CAS  Google Scholar 

  6. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491–496, 1989.

    Article  Google Scholar 

  7. McGuire WL. Adjuvant therapy of node-negative breast cancer (editorial). N Engl J Med 320:525–527, 1989.

    Article  PubMed  CAS  Google Scholar 

  8. DiVita VT Jr. Breast cancer therapy: Exercising all our options (editorial). N Engl J Med 320:527–529, 1989.

    Article  Google Scholar 

  9. Fisher ER, Gregorio RM, Fisher B, et al. The pathology of invasive breast cancer. Cancer 36:1–85, 1975.

    Article  PubMed  CAS  Google Scholar 

  10. Carter CL, Allen C, and Henson D. Five year survival of breast cancer by histology, tumor size, and extent of axillary lymph node involvement. Proc 14th Int Cancer Congress 3:53–62, 1987.

    Google Scholar 

  11. Berg JW and Robbins GF. Factors influencing short and long-term survival of breast cancer patients. Surg Gynecol Obstet 122:1311–1316, 1966.

    PubMed  CAS  Google Scholar 

  12. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: An NSABP update. Cancer 52:1551–1557, 1983.

    Article  PubMed  CAS  Google Scholar 

  13. Fisher B, Slack NH, Bross DM, and Cooperating Investigators. Cancer of the breast: Size of neoplasm and prognosis. Cancer 24:1071–1080, 1969.

    Article  PubMed  CAS  Google Scholar 

  14. Adair F, Berg J, Joubert L, et al. Long-term follow-up of breast cancer patients. A 30-year report. Cancer 33:1145–1150, 1974.

    Article  PubMed  CAS  Google Scholar 

  15. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45:2917–2924, 1980.

    Article  PubMed  CAS  Google Scholar 

  16. Koscielny S, Tubiana M, Le MG, et al. Breast cancer: Relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49: 709–715, 1984.

    Article  PubMed  CAS  Google Scholar 

  17. Moon TE, Jones SE, Bonadonna G, et al. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 10:396–403, 1987.

    Article  PubMed  CAS  Google Scholar 

  18. Carter CL, Allen C, and Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187, 1989.

    Article  PubMed  CAS  Google Scholar 

  19. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239–1251, 1989.

    PubMed  CAS  Google Scholar 

  20. Rosen PP, Groshen S, Saigo PE, et al. A long-term follow-up study of survival in stage I (T1N1M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355–366, 1989.

    PubMed  CAS  Google Scholar 

  21. Bloom HJ and Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377, 1957.

    Article  PubMed  CAS  Google Scholar 

  22. Scarff RW and Torioni H. Histological typing of breast tumors. Geneve, WHO 13-20, 1968.

    Google Scholar 

  23. Fisher ER, Redmond C and Fisher B. Histologic grading of breast cancer. Pathol Ann 15:239–251, 1980.

    CAS  Google Scholar 

  24. Davies BW, Gelber D, Goldhirsh, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662–2670, 1986.

    Article  Google Scholar 

  25. Contesso G, Mouriesse H, Friedman S, et al. The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave Roussy. J Clin Oncol 5:1378–1386, 1987.

    PubMed  CAS  Google Scholar 

  26. Rank F, Dombernowsky P, Bang Jespersen NC, et al. Histologic malignancy grading of invasive ductal breast carcinoma: A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial. Cancer 60:1299–1305, 1987.

    Article  PubMed  CAS  Google Scholar 

  27. le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:1914–1921, 1989.

    Article  PubMed  Google Scholar 

  28. le Doussal V, Tubiana-Hulin M, Hacene K, et al. Nuclear characteristics as indicators of prognosis in node negative breast cancer patients. Breast Cancer Res Treat 14:207–216, 1989.

    Article  PubMed  Google Scholar 

  29. Fisher B, Redmond C, Fisher ER, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076–1087, 1988.

    PubMed  CAS  Google Scholar 

  30. Bustamante-Montes MA, Clark G, Langone G, et al. Histopathological grading of breast specimens correlates with disease-free survival in node-negative breast cancer patients (abstr). Proc Am Assoc Cancer Res 30:252, 1989.

    Google Scholar 

  31. Crosby CH and Barclay THC. Carcinoma of the breast: Surgical management of patients with special conditions. Cancer 28:1628–1636, 1971.

    Article  PubMed  CAS  Google Scholar 

  32. Stoll BA. Does the malignancy of breast cancer vary with age? Clin Oncol 2:73–80, 1976.

    PubMed  CAS  Google Scholar 

  33. Ribeiro GG and Swidell R. The prognosis of breast carcinoma in women aged less than 40 years. Clin Radiol 32:213–236, 1981.

    Article  Google Scholar 

  34. Noyes RD, Spanos WJ and Montague ED. Breast cancer in women aged 30 and under. Cancer 49:1302–1307, 1982.

    Article  PubMed  CAS  Google Scholar 

  35. Adami HO, Malker B, Meirik O, et al. Age as a prognostic factor in breast cancer. Cancer 56:898–902, 1985.

    Article  PubMed  CAS  Google Scholar 

  36. Host H and Lund E. Age as a prognostic factor in breast cancer. Cancer 57:2217–2221, 1986.

    Article  PubMed  CAS  Google Scholar 

  37. Hakama M and Rihimaki H. End results of breast cancer patients in Finland 1953–1968. Ann Clin Res 6:115–121, 1974.

    PubMed  CAS  Google Scholar 

  38. Langlands AO, Pocock JP, Keww GR, and Gore SM. Long-term survival of patients with breast cancer: A study of the curability of the disease. Br Med J 2:1247–1251, 1979.

    Article  PubMed  CAS  Google Scholar 

  39. Rutqvist LE and Wallgren A. The influence of age on outcome in breast cancer. Acta Radiol Oncol 22:289–294, 1983.

    Article  PubMed  CAS  Google Scholar 

  40. Mueller CB, Ames F and Anderson GD. Breast cancer in 3558 women: Age as a significant determinant in the rate of dying and causes of death. Surgery 83:123–132, 1978.

    PubMed  CAS  Google Scholar 

  41. Cutler SJ and Axtell LM. Adjustment of long-term survival rates for deaths due to intercurrent disease. J Chron Dis 2:485–491, 1969.

    Article  Google Scholar 

  42. Wallgren A, Silfersward C and Hultborn A. Carcinoma of the breast in women under 30 years of age: A clinical and histopathological study of all cases reported as carcinoma to the Swedish Cancer Registry 1958–1968. Cancer 40:916–923, 1977.

    Article  PubMed  CAS  Google Scholar 

  43. Hibberd AD, Horwood LJ and Wells JE. Long term prognosis of women with breast cancer in New Zealand: Study of survival to 30 years. Br Med J 286:1777–1779, 1983.

    Article  CAS  Google Scholar 

  44. Falkson G, Gelman RS and Pretorius FJ. Age as a prognostic factor in recurrent breast cancer. J Clin Oncol 4:663–671, 1986.

    PubMed  CAS  Google Scholar 

  45. Dressier LG, Seamer LC, Owens MA, et al. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61:420–427, 1988.

    Article  Google Scholar 

  46. Knight WA III, Livingston RB, Gregory EJ, et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671, 1977.

    PubMed  CAS  Google Scholar 

  47. Allegra JC, Lippman ME, Simon R, et al. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 63:1271–1277, 1979.

    PubMed  CAS  Google Scholar 

  48. Hahnel R, Woodings T and Vivian AB. Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671–675, 1979.

    Article  PubMed  CAS  Google Scholar 

  49. Cooke T, George WD and Griffiths K. Possible tests for selection of adjuvant systemic therapy in early cancer of the breast. Br J Surg 67:747–750, 1980.

    Article  PubMed  CAS  Google Scholar 

  50. Valagussa P, Di Fronzo G, Bignami P, et al. Prognostic importance of estrogen receptors to select node negative patients for adjuvant chemotherapy. In: Adjuvant Therapy of Cancer III, SE Salmon and SE Jones (eds). Philadelphia: Grune & Stratton, 1981, pp. 329–333.

    Google Scholar 

  51. Crowe JP, Hubay CA, Pearson OH, et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 2:171–176, 1982.

    Article  PubMed  CAS  Google Scholar 

  52. Adami HO, Graffman S, Lindgren A and Sallstrom J. Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 5:293–300, 1985.

    Article  PubMed  CAS  Google Scholar 

  53. Clark GM and McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20–25, 1988.

    PubMed  CAS  Google Scholar 

  54. Brooklehurst D, Wilde CE, Finbow JAH, et al. Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: A short-term study. Clin Chem 35:238–240, 1989.

    Google Scholar 

  55. Kinne DW, Ashikari R, Butler A, et al. Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47:2364–2367, 1981.

    Article  PubMed  CAS  Google Scholar 

  56. Samaan NA, Buzdar AU, Aldinger KA, et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 47:554–560, 1981.

    Article  PubMed  CAS  Google Scholar 

  57. Sears HF, Janus C, Levy W, et al. Breast cancer without axillary metastases: Are there high-risk biologic subpopulations? Cancer 50:1820–1827, 1982.

    Article  PubMed  CAS  Google Scholar 

  58. Shapiro CM, Schifeling D, Bitran JD, et al. Prognostic value of the estrogen receptor level in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol 19:119–121, 1982.

    Article  PubMed  CAS  Google Scholar 

  59. Mason BH, Holdaway IM, Mullins PR, et al. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43:2985–2990, 1983.

    PubMed  CAS  Google Scholar 

  60. Parl FF, Schmidt BP, Dupont WD, et al. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor size, axillary node metastasis, and histopathologic grading. Cancer 54:2237–2242, 1984.

    Article  PubMed  CAS  Google Scholar 

  61. Butler JA, Bretsky S, Menendez-Botet C, et al. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 55:1178–1181, 1985.

    Article  PubMed  CAS  Google Scholar 

  62. Williams MR, Nicholson RI, Elston CW, et al. Oestrogen receptors in primary breast cancer. Br J Cancer 51:907–909, 1985.

    Article  PubMed  CAS  Google Scholar 

  63. Caldarola L, Volterrani P, Caldarola B, et al. The influence of hormone receptors and hormonal adjuvant therapy on disease-free survival in breast cancer: A multifactorial analysis. Eur J Cancer Clin Oncol 22:151–155, 1986.

    Article  PubMed  CAS  Google Scholar 

  64. Thorpe SM, Rose C, Rasmussen BB, et al. Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47:6126–6133, 1987.

    PubMed  CAS  Google Scholar 

  65. Stenkvist B, Bengtsson E, Dahlqvist B, et al. Predicting breast cancer recurrence. Cancer 50:2884–2893, 1982.

    Article  PubMed  CAS  Google Scholar 

  66. Baak JPA, van Dop H, Kurver PHJ and Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 56:374–382, 1985.

    Article  PubMed  CAS  Google Scholar 

  67. Meyer JS, McDivitt RW, Stone KR, et al. Practical breast carcinoma cell kinetics: Review and update. Breast Cancer Res Treat 4:79–88, 1984.

    Article  PubMed  CAS  Google Scholar 

  68. Tubiana M, Pejovic MJ, Renaud A, et al. Kinetic parameters and the course of the disease in breast cancer. Cancer 47:937–943, 1981.

    Article  PubMed  CAS  Google Scholar 

  69. Tubiana M, Pejovic MH, Chavaudra N, et al. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 33:441–445, 1984.

    Article  PubMed  CAS  Google Scholar 

  70. Tubiana M, Pejovic MH, Koscielny S, et al. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 44:17–22, 1989.

    Article  PubMed  CAS  Google Scholar 

  71. Gentili C, Sanfilippo O and Silvestrini R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 48:974–979, 1981.

    Article  PubMed  CAS  Google Scholar 

  72. Silvestrini R, Daidone MG and Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56:1982–1987, 1985.

    Article  PubMed  CAS  Google Scholar 

  73. Silvestrini R, Daidone MG, Di Fronzo G, et al. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7:161–169, 1986.

    Article  PubMed  CAS  Google Scholar 

  74. Meyer JS, Friedman E, McCrate M, et al. Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51:1879–1886, 1983.

    Article  PubMed  CAS  Google Scholar 

  75. Hery M, Gioanni J, Lalanne C-M, et al. The DNA labelling index: A prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 9:207–211, 1987.

    Article  PubMed  CAS  Google Scholar 

  76. Bonadonna G, Valagussa P, Tancini G, et al. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1:45–49, 1986.

    PubMed  Google Scholar 

  77. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715, 1984.

    PubMed  CAS  Google Scholar 

  78. Gerdes J, Lelle RJ, Pickartz H, et al. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 39:977–980, 1986.

    Article  PubMed  CAS  Google Scholar 

  79. Charpin C, Andrac L, Vacheret H, et al. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res 48:4368–4374, 1988.

    PubMed  CAS  Google Scholar 

  80. Walker RA and Camplejohn RS. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer 57:281–283, 1988.

    Article  PubMed  CAS  Google Scholar 

  81. Gasparini G, Dal Fior S, Pozza F and Bevilacqua P. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat 14:329–336, 1989.

    Article  PubMed  CAS  Google Scholar 

  82. Merkel DE and McGuire WL. Ploidy, proliferative activity and prognosis. Cancer 65:1194–1205, 1990.

    Article  PubMed  CAS  Google Scholar 

  83. Ewers S-B, Langstrom E, Baldetorp B and Killander D. Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry 5:408–419, 1984.

    Article  PubMed  CAS  Google Scholar 

  84. Thorud E, Fossa SD, Vaage S, et al. Primary breast cancer: Flow cytometric DNA pattern in relation to clinical and histopathologic characteristics. Cancer 57:808–811, 1986.

    Article  PubMed  CAS  Google Scholar 

  85. Kallioniemi O-P, Blanco G, Alavaikko M, et al. Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 5:637–642, 1987.

    Article  Google Scholar 

  86. Kallioniemi O-P, Blanco G, Alavaikko M, et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histograms in breast cancer. Cancer 62:2183–2190, 1988.

    Article  PubMed  CAS  Google Scholar 

  87. Cornelisse CJ, van de Velde CJH, Caspers RJC, et al. DNA ploidy and survival in breast cancer patients. Cytometry 8:225–234, 1987.

    Article  PubMed  CAS  Google Scholar 

  88. Muss HB, Kute TE, Case LD, et al. The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64:1894–1900, 1989.

    Article  PubMed  CAS  Google Scholar 

  89. Clark GM, Dressler LG, Owens MA, et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627–633, 1989.

    Article  PubMed  CAS  Google Scholar 

  90. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 322:1045–1053, 1990.

    Article  PubMed  CAS  Google Scholar 

  91. Osborne CK and Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: Clinical implications. Breast Cancer Res Treat 15:3–11, 1990.

    Article  PubMed  CAS  Google Scholar 

  92. Cappelletti V, Brivio M, Miodini P, et al. Simultaneous estimation of epidermal growth factor receptors and steroid receptors in a series of 136 resectable primary breast tumors. Tumor Biol 9:200–211, 1988.

    Article  CAS  Google Scholar 

  93. Sainsbury JRC, Malcom AJ, Appleton DR, et al. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38:1225–1228, 1985.

    Article  PubMed  CAS  Google Scholar 

  94. Skoog L, Macias A, Azavedo E, et al. Receptors for EGF and oestradiol and thymidine kinase activity in different histological subgroups of human mammary carcinomas. Br J Cancer 54:271–276, 1986.

    Article  PubMed  CAS  Google Scholar 

  95. Walker RA and Camplejohn RS. DNA flow cytometry of human breast carcinomas and its relationship to transferrin and epidermal growth factor receptors. J Pathol 150:37–42, 1986.

    Article  PubMed  CAS  Google Scholar 

  96. Macias A, Azavedo E, Hagerstrom T, et al. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res 7:459–464, 1987.

    PubMed  CAS  Google Scholar 

  97. Spitzer E, Grosse R, Kunde D and Schmidt HE. Growth of mammary epithelial cells in breast-cancer biopsies correlates with EGF binding. Int J Cancer 39:279–282, 1987.

    Article  PubMed  CAS  Google Scholar 

  98. Sainsbury JCR, Farndon JR, Needham GK, et al. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398–1402, 1987.

    PubMed  CAS  Google Scholar 

  99. Rios MA, Macias A, Perez R, et al. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8:173–176, 1988.

    PubMed  CAS  Google Scholar 

  100. Grimaux M, Romain S, Remvikos Y, et al. Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res Treat 14:77–90, 1989.

    Article  PubMed  CAS  Google Scholar 

  101. Masiakowski P, Breathnach R, Bloch J, et al. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acid Res 10:7895–7903, 1982.

    Article  PubMed  CAS  Google Scholar 

  102. Jakowlev SB, Breathnach R, Jeltsch JM, et al. Sequence of pS2 mRNA induced by estrogen in the human breast cancer cell line. Nucleic Acid Res 12:2861–2878, 1984.

    Article  Google Scholar 

  103. Rio MC, Bellocq JP, Gairard B, et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84:9243–9347, 1987.

    Article  PubMed  CAS  Google Scholar 

  104. Schwartz L, Koerner F, Stracher M, et al. Prognostic significance of pS2 in primary breast carcinoma value in lymph node negative breast cancer (abstr). Proc Am Soc Clin Oncol 8:43, 1989.

    Google Scholar 

  105. Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008–6014, 1989.

    PubMed  CAS  Google Scholar 

  106. Spyratos F, Maudelone T, Brouillet J-P, et al. Cathepsin D: An independent prognostic factor for metastasis of breast cancer. Lancet 2:1115–1118, 1989.

    Article  PubMed  CAS  Google Scholar 

  107. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297–302, 1990.

    Article  PubMed  CAS  Google Scholar 

  108. Pekonen F, Partanen S, Makinen T and Rutanen E-M. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:1343–1347, 1988.

    PubMed  CAS  Google Scholar 

  109. Foekens JA, Portengen H, van Putten WLJ, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989.

    PubMed  CAS  Google Scholar 

  110. Bonneterre J, Peyrat JP and Beuscart R. Prognostic significance of prolactin receptors in human breast cancer. Cancer Res 47:4724–4728, 1987.

    PubMed  CAS  Google Scholar 

  111. Marques LA, Franco ELF, Torloni H, et al. Independent prognostic value of laminin receptor expression in breast cancer survival. Cancer Res 50:1479–1483, 1990.

    PubMed  CAS  Google Scholar 

  112. Kuhajda FP, Piantadosi S and Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636–641, 1989.

    Article  PubMed  CAS  Google Scholar 

  113. Cline MJ, Battifora H and Yokota J. Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease. J Clin Oncol 5:999–1006, 1987.

    PubMed  CAS  Google Scholar 

  114. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987.

    Article  PubMed  CAS  Google Scholar 

  115. Varley JM, Swallow JE, Brammar WJ, et al. Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1:423–430, 1987.

    PubMed  CAS  Google Scholar 

  116. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49:3104–3108, 1989.

    PubMed  CAS  Google Scholar 

  117. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1989.

    Article  PubMed  CAS  Google Scholar 

  118. Ro J, Naggar AE, Ro JY, et al. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49:6941–6944, 1989.

    PubMed  CAS  Google Scholar 

  119. Ali IU, Campbell G, Lidereau R, et al. Amplification of c-erbB-2 and aggressive human breast tumors? (Technical comments) Science 240:1795–1796, 1988.

    Google Scholar 

  120. Zhou D-J, Ahuja H and Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene 4:105–108, 1989.

    PubMed  CAS  Google Scholar 

  121. Slamon DJ and Clark GM. Response to technical comments. Science 240:1796–1798, 1988.

    Article  PubMed  CAS  Google Scholar 

  122. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087–2090, 1989.

    PubMed  CAS  Google Scholar 

  123. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120–1128, 1989.

    PubMed  CAS  Google Scholar 

  124. van de Vijver MJ, Peterse JL, Moot WJ, et al. Neu protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer. N Engl J Med 319:1239–1245, 1988.

    Article  PubMed  Google Scholar 

  125. Thor AD, Schwartz LH, Koerner FC, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49:7147–7152, 1989.

    PubMed  CAS  Google Scholar 

  126. Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer, 42:842–845, 1988.

    Article  PubMed  CAS  Google Scholar 

  127. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112, 1990.

    PubMed  CAS  Google Scholar 

  128. Allred DC, Clark GM, Molina R, et al. Immunocytochemical evaluation of HER-2/neu oncogene expression in different evolutionary stages of breast carcinoma and correlation with clinical-pathological characteristics (abstr). Am Soc Clin Oncol 9:23, 1990.

    Google Scholar 

  129. Allred D, Clark G, Tandon A, et al. HER-2/neu expression identified a group of node-negative breast cancer patients at high risk for recurrence (abstr). Am Soc Clin Oncol 9:23, 1990.

    Google Scholar 

  130. Escot C, Theillet C, Lidereau R, et al. Genetic alteration of the c-myc proto-oncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83:4834–4838, 1986.

    Article  PubMed  CAS  Google Scholar 

  131. Theillet C, Lidereau R, Escot C, et al. Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res 46:4776–4781, 1986.

    PubMed  CAS  Google Scholar 

  132. Spandidos DA. Oncogene activation in malignant transformation: A study of H-ras in human breast cancer. Anticancer Res 7:991–996, 1987.

    PubMed  CAS  Google Scholar 

  133. Lundy J, Grimson R, Mishriki Y, et al. Elevated ras oncogene expression correlates with lymph node metastses in breast cancer patients. J Clin Oncol 4:1321–1325, 1986.

    PubMed  CAS  Google Scholar 

  134. Querzoli P, Marchetti E, Bagni, et al. Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status. Breast Cancer Res Treat 12:23–30, 1988.

    Article  PubMed  CAS  Google Scholar 

  135. Czerniak B, Chen R, Tuziak T, et al. Expression of oncogene p21 protein in relation to regional spread of human breast carcinomas. Cancer 63:2008–2013, 1989.

    Article  PubMed  CAS  Google Scholar 

  136. Podhajcer OL, Bravo AI, Dain L, et al. In vitro analysis of the cellular proliferative response to 17-B-estradiol of human breast cancer. Cancer 61:1807–1812, 1988.

    Article  PubMed  CAS  Google Scholar 

  137. Casey G, Smith R, McGillivray D, et al. Characterization and chromosome assignments of the human homolog of int-2, a potential proto-oncogene. Mol Cell Biol 6:502–510, 1986.

    PubMed  CAS  Google Scholar 

  138. Lidereau R, Callahan R, Dickson C, et al. Amplification of the int-2 gene in primary human breast tumors. Oncogene Res 2:286–291, 1988.

    Google Scholar 

  139. Haybittle JL, Blarney RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 45:361–366, 1982.

    Article  PubMed  CAS  Google Scholar 

  140. Shek LM and Godolphin W. Model for breast cancer survival: Relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48:5565–5569, 1988.

    PubMed  CAS  Google Scholar 

  141. Russo J, Frederick J, Ownby HE, et al. Predictors of recurrence and survival of patients with breast cancer. J Clin Path 88:123–131, 1987.

    CAS  Google Scholar 

  142. Cox DR. Regression models and life-tables. J R Statist Soc [B] 34:187–202, 1972.

    Google Scholar 

  143. Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56:489–492, 1987.

    Article  PubMed  CAS  Google Scholar 

  144. van der Linden JC, Lindeman J, Baak JPA, et al. The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry 10:56–61, 1989.

    Article  PubMed  Google Scholar 

  145. Ciampi A, Lawless JF, McKinney SM and Singhai K. Regression and recursive partition strategies in the analysis of medical survival data. J Clin Epidemiol 8:737–748, 1988.

    Article  Google Scholar 

  146. Norton L and Simon R. Tumor size, sensitivity to therapy, and the design of cancer treatment. Cancer Treat Rep 61:1307–1317, 1977.

    PubMed  CAS  Google Scholar 

  147. Goldie JH and Coldman AJA. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1773, 1979.

    PubMed  CAS  Google Scholar 

  148. Speer JF, Petrovsky VE, Retsky MW and Wardwell RH. A stochastic numerical model of breast cancer that simulates clinical data. Cancer Res 44:4124–4130, 1984.

    PubMed  CAS  Google Scholar 

  149. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 48: 7067–7071, 1988.

    PubMed  CAS  Google Scholar 

  150. McGuire WL, Tandon AK, Allred DC, Chamness GC and Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst, 82:1006–1015, 1990.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gary M. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William L. McGuire
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, San Francisco, USA

    I. Craig Henderson

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Clark, G.M., McGuire, W.L. (1992). Defining the high-risk breast cancer patient. In: Henderson, I.C. (eds) Adjuvant Therapy of Breast Cancer. Cancer Treatment and Research, vol 60. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3496-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3496-9_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6550-1

  • Online ISBN: 978-1-4615-3496-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation